Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition

Journal of Cardiovascular Pharmacology

Volumn 35, Issue 1, 2000, Pages 136-144

  Bandoh, Tsutomu ^a,c   Mitani, Hironobu ^a,c   Niihashi, Mari ^b   Kusumi, Yoshiaki ^b   Kimura, Masaaki ^a   Ishikawa, Junji ^a   Totsuka, Tetsuya ^a   Sakurai, Isamu ^b   Hayashi, Shigehiro ^a  

^a Banyu Tsukuba Research Institute   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c NOVARTIS PHARMA K K   (Japan)

Author keywords

Atherosclerosis; Endothelium; Fluvastatin; Lipid peroxide; Macrophage

Indexed keywords

ACETYLCHOLINE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID PEROXIDE; PRAVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY ENDOTHELIUM; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFECT; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; CHOLESTEROL, DIETARY; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FATTY ACIDS, MONOUNSATURATED; HEMOLYTIC PLAQUE TECHNIQUE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIPID PEROXIDATION; LIPID PEROXIDES; LIPIDS; MACROPHAGES; MALE; MUSCLE, SMOOTH, VASCULAR; PRAVASTATIN; RABBITS; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 0033987474     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200001000-00018     Document Type: Article

References (4)

1. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994;16:366-85.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. Mao SJT, Yates MT, Rechtin AE, Jackson RL, Van Sickle WA. Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits. J Med Chem 1991;34:298-302.
4. Corsini A, Mazzotti M, Raiteri M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993;101:117-25.